1 week ago
10
Soumya Eswaran
Tue, April 21, 2026 astatine 9:33 AM CDT 3 min read
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 capitalist missive for “Meridian Small Cap Growth Fund”. A transcript of the missive is disposable to download here. The US equities marketplace started 2026 with volatility driven by commercialized argumentation uncertainty and heightened geopolitical risks. Initial gains were attributed to assurance successful home companies and the Federal Reserve easing. However, sentiment deteriorated pursuing accrued tariffs and subject strikes by the U.S. and Israel against Iran. During the quarter, Meridian Small Cap Growth Fund returned -8.37% compared to the Russell 2000 Growth Index’s -2.82% return. The Fund’s comparative underperformance was driven by manufacture allocation effects, portion banal enactment contributed positively. Despite the marketplace environment, the money prioritizes high-quality businesses characterized by durable competitory advantages, robust equilibrium sheets, and a wide outlook for sustainable net growth. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2026.
In its first-quarter 2026 capitalist letter, Meridian Small Cap Growth Fund highlighted stocks similar CG Oncology, Inc. (NASDAQ:CGON). CG Oncology, Inc. (NASDAQ:CGON) is simply a late-stage objective biopharmaceutical institution specializing successful processing cretostimogene grenadenorepvec for patients with bladder cancer. On April 20, 2026, CG Oncology, Inc. (NASDAQ:CGON) closed astatine $70.40 per share. One-month instrumentality of CG Oncology, Inc. (NASDAQ:CGON) was 10.28%, and its shares gained 243.75% implicit the past 52 weeks. CG Oncology, Inc. (NASDAQ:CGON) has a marketplace capitalization of $5.94 billion.
Meridian Small Cap Growth Fund stated the pursuing regarding CG Oncology, Inc. (NASDAQ:CGON) successful its Q1 2026 capitalist letter:
"CG Oncology, Inc. (NASDAQ:CGON) is simply a clinical-stage biotechnology institution processing oncolytic immunotherapies for bladder cancer. The institution targets non-muscle invasive bladder cancer, a ample and underserved marketplace wherever existing treatments transportation important side-effect profiles, positioning its pb campaigner arsenic a differentiated therapeutic alternative. Shares precocious sharply pursuing the merchandise of pivotal objective information that exceeded expectations, reinforcing the competitory imaginable of the company’s pb program. The beardown efficacy signals drove renewed capitalist involvement and positioned the institution favorably up of cardinal regulatory milestones that could further unlock value."
CG Oncology, Inc. (NASDAQ:CGON) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 35 hedge money portfolios held CG Oncology, Inc. (NASDAQ:CGON) astatine the extremity of the 4th quarter, up from 34 successful the erstwhile quarter. While we admit the imaginable of CG Oncology, Inc. (NASDAQ:CGON) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
English (CA) · 
English (US) · 
Spanish (MX) ·